AgenusInc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that data from an investigator-initiated Phase II trial conducted at Memorial Sloan Kettering Cancer Center will be ...
The biggest stories of the day delivered to your inbox.
Approximately 1,200 patients have been treated with botensilimab and/or balstilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus’ investigational PD-1 ...
LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc (AGEN). (Nasdaq: AGEN) today reported financial results for the fourth quarter and full year ended December 31, 2025, highlighting progress for the ...
Agenus Inc. (Nasdaq: AGEN) today reported financial results for the fourth quarter and full year ended December 31, 2025, highlighting progress for the botensilimab (BOT) plus balstilimab (BAL) ...
Agenus Inc. (NASDAQ:AGEN) is one of the most undervalued penny stocks to buy right now. On February 19, Agenus presented new translational and clinical biomarker data from its Phase 1b C-800-01 trial, ...
The PS5 gaming library keeps growing with mid-generation hits and PS Plus Extra additions, making now an ideal time to dive into standout releases. From superhero escapades to emotional indie journeys ...
AstraZeneca is taking its oral GLP-1 drug into phase 3 on the back of a pair of midstage weight loss wins, despite remaining tight-lipped on how the candidate actually performed. The U.K.-based Big ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results